ArticleAmerican journal of clinical and experimental immunology2012
Interleukin 13 and the evolution of asthma therapy.
Article in American journal of clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma.PloS one · 2019Pooled it
- Inhibition of γ-glutamyl transferase suppresses airway hyperresponsiveness and airway inflammation in a mouse model of steroid resistant asthma exacerbation.Frontiers in immunology · 2023Article
- Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection.Clinical and experimental immunology · 2021Article
- Potential influence of Nagella sativa (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Review
- IL-33/ST2 axis deficiency exacerbates neutrophil-dominant allergic airway inflammation.Clinical & translational immunology · 2021Article
- MiR-1165-3p Suppresses Th2 Differentiation via Targeting IL-13 and PPM1A in a Mouse Model of Allergic Airway Inflammation.Allergy, asthma & immunology research · 2020Article
- Surprisingly Fast Interface and Elbow Angle Dynamics of Antigen-Binding Fragments.Frontiers in molecular biosciences · 2020Article
- Antibody humanization-the Influence of the antibody framework on the CDR-H3 loop ensemble in solution.Protein engineering, design & selection : PEDS · 2019Article
- Transitions of CDR-L3 Loop Canonical Cluster Conformations on the Micro-to-Millisecond Timescale.Frontiers in immunology · 2019Article
- Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs.Biomarker insights · 2015Review
- Deciphering Asthma Biomarkers with Protein Profiling Technology.International journal of inflammation · 2015Review
- Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution.Pulmonary circulation · 2014Article
- Regulation of IFN-γ by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia.European journal of immunology · 2014Article
- Genetic polymorphisms and asthma: findings from a case-control study in the Madeira island population.Biological research · 2014Article
- Re-defining the unique roles for eosinophils in allergic respiratory inflammation.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2014Review
- Aligning mouse models of asthma to human endotypes of disease.Respirology (Carlton, Vic.) · 2014Review
- Perspective: ambient air pollution: inflammatory response and effects on the lung's vasculature.Pulmonary circulation · 2014Review
- Effect of Alpha-Hederin, the active constituent of Nigella sativa, on miRNA-126, IL-13 mRNA levels and inflammation of lungs in ovalbumin-sensitized male rats.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
This is a concise review on Interleukin (IL)-13 and the evolution of asthma therapy, from discovery of the molecule, the identification of its pathogenic role in animal models of asthma, to the development of clinically successful neutralizing agents. The translational path from basic research to clinical application was not sequential as expected but random with respect to the tools (molecular & cell biology, animal models, human studies) used and to the application of academic versus industry research. The experiences with the development of neutralizing anti-IL-13 reagents emphasize the need for inclusion of a biomarker assay in the clinical trials that both identifies individuals that actually have aberrant expression of the pathway of interest and allows determining whether the target of interest is neutralized.
Indexed as
Identifiers
23607082PMC3630076W168047392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.